Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

SANUWAVE Health (SNWV) EBITDA (2016 - 2026)

SANUWAVE Health has reported EBITDA over the past 17 years, most recently at -$1.4 million for Q1 2026.

  • Quarterly EBITDA rose 76.48% to -$1.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Mar 2026, up 147.95% year-over-year, with the annual reading at $11.8 million for FY2025, 135.84% up from the prior year.
  • EBITDA was -$1.4 million for Q1 2026 at SANUWAVE Health, down from $7.7 million in the prior quarter.
  • Over five years, EBITDA peaked at $18.2 million in Q4 2023 and troughed at -$23.7 million in Q3 2023.
  • The 5-year median for EBITDA is -$4.7 million (2024), against an average of -$3.5 million.
  • The largest YoY upside for EBITDA was 419.41% in 2023 against a maximum downside of 1980.16% in 2023.
  • A 5-year view of EBITDA shows it stood at -$5.7 million in 2022, then skyrocketed by 419.41% to $18.2 million in 2023, then tumbled by 173.12% to -$13.3 million in 2024, then surged by 157.81% to $7.7 million in 2025, then plummeted by 118.71% to -$1.4 million in 2026.
  • Per Business Quant, the three most recent readings for SNWV's EBITDA are -$1.4 million (Q1 2026), $7.7 million (Q4 2025), and $9.7 million (Q3 2025).